DAVENPORT & Co LLC Cuts Stock Holdings in Teva Pharmaceutical Industries Ltd. $TEVA

DAVENPORT & Co LLC lowered its position in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 37.2% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 212,737 shares of the company’s stock after selling 125,968 shares during the period. DAVENPORT & Co LLC’s holdings in Teva Pharmaceutical Industries were worth $6,640,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds also recently added to or reduced their stakes in TEVA. Phoenix Financial Ltd. increased its holdings in shares of Teva Pharmaceutical Industries by 9.4% in the 3rd quarter. Phoenix Financial Ltd. now owns 41,295,244 shares of the company’s stock worth $834,164,000 after purchasing an additional 3,533,800 shares in the last quarter. National Pension Service lifted its holdings in shares of Teva Pharmaceutical Industries by 24.2% during the third quarter. National Pension Service now owns 2,073,293 shares of the company’s stock valued at $41,881,000 after purchasing an additional 404,526 shares in the last quarter. Public Sector Pension Investment Board boosted its position in shares of Teva Pharmaceutical Industries by 11.5% during the third quarter. Public Sector Pension Investment Board now owns 670,467 shares of the company’s stock valued at $13,543,000 after buying an additional 69,000 shares during the last quarter. Oak Harvest Investment Services bought a new stake in Teva Pharmaceutical Industries in the 3rd quarter worth about $1,010,000. Finally, Harel Insurance Investments & Financial Services Ltd. increased its holdings in Teva Pharmaceutical Industries by 12.9% in the 3rd quarter. Harel Insurance Investments & Financial Services Ltd. now owns 37,696,690 shares of the company’s stock worth $761,455,000 after buying an additional 4,306,363 shares in the last quarter. 54.05% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

TEVA has been the subject of a number of recent analyst reports. Scotiabank boosted their target price on Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the stock a “sector outperform” rating in a research report on Thursday, January 29th. Wall Street Zen upgraded shares of Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research note on Saturday, January 31st. Weiss Ratings reissued a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a report on Wednesday, January 21st. JPMorgan Chase & Co. raised their target price on shares of Teva Pharmaceutical Industries from $28.00 to $35.00 and gave the stock an “overweight” rating in a report on Tuesday, December 16th. Finally, Piper Sandler reaffirmed an “overweight” rating and issued a $41.00 target price (up from $40.00) on shares of Teva Pharmaceutical Industries in a research report on Wednesday, March 4th. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Teva Pharmaceutical Industries presently has an average rating of “Moderate Buy” and a consensus price target of $37.67.

Teva Pharmaceutical Industries Trading Up 1.1%

Shares of NYSE:TEVA opened at $29.78 on Friday. The stock’s 50-day simple moving average is $32.40 and its two-hundred day simple moving average is $27.30. The stock has a market capitalization of $34.24 billion, a price-to-earnings ratio of 24.82, a PEG ratio of 9.86 and a beta of 0.72. Teva Pharmaceutical Industries Ltd. has a 52-week low of $12.47 and a 52-week high of $37.35. The company has a debt-to-equity ratio of 1.89, a quick ratio of 0.80 and a current ratio of 1.04.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings results on Wednesday, January 28th. The company reported $0.96 EPS for the quarter, beating the consensus estimate of $0.65 by $0.31. The firm had revenue of $4.71 billion during the quarter, compared to analyst estimates of $4.36 billion. Teva Pharmaceutical Industries had a net margin of 8.16% and a return on equity of 46.28%. The business’s revenue for the quarter was up 11.4% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.71 EPS. Teva Pharmaceutical Industries has set its FY 2026 guidance at 2.570-2.770 EPS. Analysts expect that Teva Pharmaceutical Industries Ltd. will post 2.5 EPS for the current year.

Insider Buying and Selling at Teva Pharmaceutical Industries

In other news, insider Mark Sabag sold 62,102 shares of the business’s stock in a transaction on Tuesday, March 17th. The shares were sold at an average price of $30.14, for a total transaction of $1,871,754.28. Following the completion of the sale, the insider owned 224,940 shares of the company’s stock, valued at $6,779,691.60. The trade was a 21.64% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Richard Daniell sold 17,295 shares of the company’s stock in a transaction on Thursday, March 5th. The stock was sold at an average price of $31.67, for a total value of $547,732.65. Following the completion of the sale, the executive vice president owned 85,755 shares of the company’s stock, valued at $2,715,860.85. This trade represents a 16.78% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 920,901 shares of company stock valued at $30,056,789 in the last quarter. Insiders own 0.49% of the company’s stock.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.